会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Therapeutic Administration Of The Scrambled Anti-Angiogenic Peptide C16Y
    • 加扰抗血管生成肽C16Y的治疗作用
    • US20080131430A1
    • 2008-06-05
    • US10588884
    • 2004-02-12
    • Karl G. CsakyHynda KleinmanLourdes Ponce
    • Karl G. CsakyHynda KleinmanLourdes Ponce
    • A61K39/44A61K38/10A61P35/00A61P27/02A61K38/08
    • A61K38/08A61K38/10C07K5/101C07K5/1016C07K14/78
    • Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
    • 不规则的血管发生与多种病理状况有关。 肿瘤生长和转移取决于新血管的发育。 眼睛中新血管的发展或眼睛新血管形成已经涉及各种严重的眼部疾病。 例如,脉络膜新生血管形成与年龄相关的黄斑变性相关,而视网膜新生血管形成与糖尿病性视网膜病变相关。 本发明基于肽体系C16Y的发现,C16Y抑制体内新生血管形成和肿瘤生长。 C16Y是来自层粘连蛋白-1的y1链的C16肽序列的加扰版本。 不同于作为血管生成刺激物的C16,C16Y已显示出抑制血管发生。 本发明公开了使用全长和截短版本的C16Y治疗眼新生血管形成和癌症的方法。
    • 5. 发明授权
    • Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
    • 加扰的抗血管生成肽C16Y的治疗施用
    • US08039585B2
    • 2011-10-18
    • US10588884
    • 2004-02-12
    • Karl G. CsakyHynda KleinmanLourdes Ponce
    • Karl G. CsakyHynda KleinmanLourdes Ponce
    • A61K38/04A61K38/00A61K51/00A61P35/00C07K5/00C07K7/00C07K16/00C07K17/00
    • A61K38/08A61K38/10C07K5/101C07K5/1016C07K14/78
    • Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
    • 不规则的血管发生与多种病理状况有关。 肿瘤生长和转移取决于新血管的发育。 眼睛中新血管的发展或眼睛新血管形成已经涉及各种严重的眼部疾病。 例如,脉络膜新生血管形成与年龄相关的黄斑变性相关,而视网膜新生血管形成与糖尿病性视网膜病变相关。 本发明基于肽体系C16Y的发现,C16Y抑制体内新生血管形成和肿瘤生长。 C16Y是来自层粘连蛋白-1的y1链的C16肽序列的加扰版本。 不同于作为血管生成刺激物的C16,C16Y已显示出抑制血管发生。 本发明公开了使用全长和截短版本的C16Y治疗眼新生血管形成和癌症的方法。